Cipla Launched Leuprolide Acetate Depot Injection in the US
Cipla Limited and its wholly owned subsidiary, Cipla USA Inc., launched Leuprolide Acetate Injection Depot 22.5 mg. The injection was approved by the US Food and Drug Administration based on a New Drug Application (NDA) submitted under the regulatory pathway 505(b)(2). According to Cipla, Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for […]
Continue Reading